Review article: the diagnostic approach and current management of chylous ascites
Executive Summary
Chylous ascites is a rare clinical condition characterized by the accumulation of milky, triglyceride-rich lymphatic fluid within the peritoneal cavity. Accounting for less than 1% of all ascites cases, it results from the traumatic or obstructive disruption of the lymphatic system. In adults, the most frequent underlying causes are abdominal malignancy (particularly lymphoma) and cirrhosis, while congenital lymphatic disorders predominate in pediatric populations.
Diagnosis is primarily confirmed through paracentesis, with an ascitic triglyceride concentration exceeding 200 mg/dL serving as the diagnostic threshold. Because chyle contains essential nutrients and immunoglobulins, its depletion can lead to severe nutritional, metabolic, and immunologic deficiencies. Consequently, management focuses on a stepwise approach: treating the underlying etiology and implementing nutritional optimization—specifically a high-protein, low-fat diet supplemented with medium-chain triglycerides (MCTs). For refractory cases, interventions such as somatostatin analogues or transjugular intrahepatic portosystemic shunts (TIPSS) may be utilized.
1. Pathophysiology and Mechanisms
Chylous ascites occurs when lymphatic flow is disrupted, leading to the extravasation of thoracic or intestinal lymph. Lymph is a complex mixture of proteins, immune cells, and lipids. Approximately half of all lymph originates in the intestine, where fatty acids are converted into triglycerides and absorbed as chylomicrons, giving the fluid its characteristic milky appearance.
The development of chylous ascites generally follows one of three pathophysiological mechanisms:
Acquired Lymphatic Disruption: Direct trauma or surgery leads to the dilation of retroperitoneal lymphatics and the formation of a lymphoperitoneal fistula. This can also occur due to increased lymph production or elevated venous pressure in conditions like cirrhosis or congestive heart failure.
Lymph Node Fibrosis: Malignancy can obstruct lymph flow from the gut into the cysterna chyli. This causes leakage from dilated subserosal lymphatics and may lead to protein-losing enteropathy and malabsorption.
Congenital Anomalies: Disorders such as congenital lymphangiectasia involve the absence of lymphatic valves, causing lymph to leak through fistulae into the peritoneal cavity.
2. Etiology
The causes of chylous ascites vary significantly by age and geographic region. While malignancy and cirrhosis account for two-thirds of atraumatic cases in Western countries, infectious causes are more prevalent in developing nations.
Table 1: Primary Etiologies and Mechanisms
Key Clinical Drivers
Malignancy: Lymphoma is the most common malignant cause, accounting for at least one-third of cases in this category.
Cirrhosis: Though only 0.5%–1% of cirrhotic ascites is chylous, portal hypertension can lead to the spontaneous rupture of serosal lymphatic channels due to excessive lymph flow (up to 20 L/day).
Infection: Mycobacterium tuberculosis and filariasis (Wuchereria bancrofti) are leading causes in Eastern and developing countries.
Post-Operative: Incidence is noted following procedures such as abdominal aneurysm repair, retroperitoneal lymphadenectomy, and liver transplants. Risk factors for post-transplant chylous ascites include low albumin and the use of vessel-sealing systems like LigaSure.
3. Diagnostic Evaluation
A thorough history and physical examination are essential, with a focus on recent trauma, surgery, and stigmata of chronic liver or renal disease. Common symptoms include abdominal distension, pain, and progressive peripheral edema.
Laboratory Analysis
Paracentesis is the mandatory diagnostic tool. The following parameters characterize chylous ascites:
Triglycerides: >200 mg/dL (Concentrations <50 mg/dL exclude the diagnosis).
Macroscopic Appearance: Turbid, thick, and milky.
Microscopic Analysis: Presence of fat globules (Sudan III stain) and a lymphocytic predominance (cell count >500).
Serum to Ascites Albumin Gradient (SAAG): Used to identify portal hypertension. A SAAG >1.1 g/dL is typical when cirrhosis is the underlying cause, while a SAAG <1.1 g/dL rules out portal hypertension.
Total Protein: Typically between 2.5 and 7.0 g/dL.
Radiological Assessment
Lymphangiography: The gold standard for identifying lymphatic obstruction, leakage, or thoracic duct patency.
Lymphoscintigraphy: Useful for assessing the effects of treatment and selecting patients for surgery.
CT and MRI: Helpful for identifying intra-abdominal masses or lymph nodes, though the density of chylous fluid on CT is often indistinguishable from simple ascites or urine.
4. Management and Treatment
Management is multifaceted, emphasizing the correction of the underlying cause alongside conservative nutritional measures.
Nutritional Optimization
Nutritional support is the cornerstone of conservative therapy. The goal is to reduce the production and flow of lymph:
Low-Fat/High-Protein Diet: Minimizes the formation of chylomicrons.
Medium-Chain Triglycerides (MCTs): MCTs (found in coconut oil and whole milk) are absorbed directly into the portal vein, bypassing the lymphatic system. Long-chain triglycerides (LCTs) must be avoided as they are transported via intestinal lymph.
Total Parenteral Nutrition (TPN): Reserved for cases where enteral measures fail, though enteral nutrition with MCTs is generally considered superior.
Pharmacological and Interventional Therapies
When conservative dietary measures are insufficient, several pharmacological and procedural options are available:
Surgical and Emerging Options
Surgical ligation or embolization of disrupted lymphatic channels may be considered for refractory cases. However, data for these interventions remain preliminary. Historically used peritoneovenous shunts are now rarely performed due to high rates of complications, including sepsis, disseminated intravascular coagulopathy, and air embolism.
5. Conclusion
Chylous ascites is a complex condition that requires a stepwise diagnostic and therapeutic approach. While rare, its impact on nutritional and immunological health necessitates prompt identification via triglyceride analysis of ascitic fluid. Conservative management—anchored by high-protein, low-fat diets supplemented with MCTs—remains the primary treatment strategy. In cases where the underlying etiology (such as malignancy or cirrhosis) is successfully managed, the prognosis for resolving the ascites improves significantly. Further research is required to optimize treatments for refractory cases where standard conservative measures fail.
